Dr. Thomas L. Holland：Careful consideration when selecting clinical outcomes brings more possibilities to clinical trials of bacterial diseases

Dr. Thomas L. Holland：Careful consideration when selecting clinical outcomes brings more possibilities to clinical trials of bacterial diseases

Staphylococcus aureus bacteremia is a major cause of bloodstream infections, and hospital-acquired bacterial pneumonia is often caused by multidrug-resistant bacteria. And developing new antibiotics requires patient-centered clinical outcomes. How to conduct a patient-centered benefit-risk assessment in the design, analysis, and interpretation of clinical trials, so that more bacterial clinical studies can achieve the expected efficacy? At the recently Infectious Disease Week (IDWeek 2023), "Infectious Disease Frontline" invited Dr. Thomas L. Holland from Duke University Medical Center to introduce the practical application and potential challenges of DOOR research on ordinal outcome, and shared its importance to future clinical trials and treatment plans.
IDWeek Commentary | Dr. Yonghong Xiao: Intestinal colonization with MDRO, horizontal transmission and risk for bloodstream infection

IDWeek Commentary | Dr. Yonghong Xiao: Intestinal colonization with MDRO, horizontal transmission and risk for bloodstream infection

Bacterial drug resistance is a significant challenge in the global public health field. Multidrug-resistant organisms (MDROs), represented by carbapenem-resistant Enterobacteriaceae (CRE), carbapenem-resistant Acinetobacter baumannii (CRAB), carbapenem-resistant Pseudomonas aeruginosa (CRPA), and vancomycin-resistant Enterococcus (VRE), exhibit high resistance and rapid transmission. Previous studies have established a close relationship between intestinal CRE colonization and infection, but the relationship between intestinal colonization and infection of other MDROs remains to be clarified. In a recent oral presentation at the 2023 Infectious Diseases Week (IDWeek 2023), a researcher reported a study on the relationship between MDRO intestinal colonization and the risk of bloodstream infection (BSI). Dr. Yonghong Xiao, from the First Affiliated Hospital, Zhejiang University School of Medicine, provides an introduction and commentary on this research.
IDWeek Live interview: Clinical Trials in Fungal Diseases That May Change Your Practice

IDWeek Live interview: Clinical Trials in Fungal Diseases That May Change Your Practice

In a special session titled "Clinical Trials That May Change Your Practice" at the 2023 Infectious Diseases Week (IDWeek 2023), Dr. George R. Thompson III of University of California Davis Medical Center presented a fascinating report on "Clinical Trials in Fungal Diseases That May Change Your Practice". He also granted an interview with "Infectious Disease Frontline"(IDF) after the conference.
Advancing Breast Cancer Control in the Philippines: Insights from Professor Corazon Ngelangel at the CCHIO Congress

Advancing Breast Cancer Control in the Philippines: Insights from Professor Corazon Ngelangel at the CCHIO Congress

Professor Corazon Ngelangel, a leading medical oncologist, recently shared her valuable insights at the CCHIO Congress. Her discussion provided a comprehensive overview of the progress in breast cancer control over the past 30 years. Professor Ngelangel's expertise and experiences, particularly in the challenging times of the pandemic, underscored the significance of such international forums for knowledge exchange and collaboration
Revolutionizing Cancer Care: Dr. Tony Ng’s Pioneering Insights at the CCHIO Congress

Revolutionizing Cancer Care: Dr. Tony Ng’s Pioneering Insights at the CCHIO Congress

Dr. Tony Ng, a renowned figure in the field of cancer research, recently participated in the 10-Day HIV-Related Congress. This event was a gathering of top minds in medicine, featuring doctors, scientists, and researchers from over 30 districts in China. Dr. Ng's role as a speaker at this congress highlighted his significant contributions to cancer research and management.
The Role of Artificial Intelligence in Medicine: Insights from an Expert

The Role of Artificial Intelligence in Medicine: Insights from an Expert

In a recent interview, a renowned expert in the field of artificial intelligence (AI) and medicine provides valuable insights into their background, experience, and contributions. The discussion explores the impact of AI in the healthcare industry, the expert's involvement in shaping health reforms in China, their industry experience at IBM, and their role in advising and mentoring startups. This article offers a comprehensive overview of the dialogue, amplifying key points and perspectives shared by Dr. Dimitris Kalogeropoulos.
ESMO Hot Topic Express | Updated Results on Patient Outcomes, Drug Exposure, Safety, and Quality of Life Relevance in the TALAPRO-2 Study

ESMO Hot Topic Express | Updated Results on Patient Outcomes, Drug Exposure, Safety, and Quality of Life Relevance in the TALAPRO-2 Study

In recent years, there have been groundbreaking advancements in the exploration of treatment modalities for prostate cancer, particularly in the use of PARP inhibitors in combination with novel hormonal therapies, offering new hope for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The TALAPRO-2 study has demonstrated that the combination of talazoparib with enzalutamide significantly improves radiographic progression-free survival (rPFS) in the overall mCRPC patient population (HR=0.63; 95% CI, 0.51–0.78; P<0.0001) and in mCRPC patients with homologous recombination repair (HRR) gene defects (HR=0.45; 95% CI, 0.33–0.61; P<0.0001) compared to placebo in combination with enzalutamide[1]. As a result, the combination therapy of talazoparib and enzalutamide received FDA approval on June 20th of this year for first-line use in mCRPC patients with HRR gene mutations.
ESMO 5-Minute Insights | DXd ADCs Shine at ESMO: Professor Jian Zhang Introduces Research in the Field of Breast Cancer

ESMO 5-Minute Insights | DXd ADCs Shine at ESMO: Professor Jian Zhang Introduces Research in the Field of Breast Cancer

ADC drugs, also known as Antibody-Drug Conjugates, combine targeted antibodies with cytotoxic drugs to accurately attack tumor cells and minimize damage to normal cells. In recent years, ADC drugs have made significant breakthroughs in the field of cancer treatment and have become a focus of attention. At this year's ESMO conference, several studies on ADC drugs garnered significant attention. In this report, Professor Jian Zhang from Fudan University-affiliated Cancer Hospital introduces the progress in the treatment of breast cancer using ADC drugs.